SLAMF7 and plasma cell myeloma: For instance, the anti-SLAMF7 therapy against multiple myeloma (MM) included a dimerization domain fused to a caspase-9 domain suicide gene to mitigate the risk of off-target activation, as SLAMF7 is expressed on healthy leukocytes, including NK cells.